Drugs / (Pyr1)apelin-13
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01590108 | Mar 2012 → Sep 2014 | idiopathic pulmonary arterial hypertension | Imperial College London | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06277336 | Mar 2024 → Mar 2025 | inappropriate ADH syndrome | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | (Pyr1)apelin-13 | “The investigators therefore hypothesize, that the administration of intravenous \[Pyr1\]apelin-13, the most common apelin isoform in the blood, increases urinary excretion” NCT06277336 ↗ |
| Route | Intravenous | “(Pyr1)apelin-13 will be infused at 30 nanomol/min intravenously.” NCT01590108 ↗ |